Toronto, Ontario–(Newsfile Corp. – March 14, 2025) – Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) (FSE: 5U9) (the “Company” or “Psyched“), a life sciences company focused on the production and distribution of health and wellness products derived from the Amanita Muscaria mushroom, is pleased to provide a corporate update to its shareholders.
In August 2020, KGK Science (“KGK“), a licensed CRO in Canada, completed a GAP analysis and Path to Market for Psyched’s flagship product as a health supplement. Throughout the fall of 2024 and into 2025, Psyched engaged various industry and regulatory experts to conduct a comprehensive review of all scientific data available in the market since the initial GAP analysis by KGK, as well as the scientific studies completed by the Company. As part of this review, Psyched Wellness is pleased to announce that it will conduct a Genotoxicity Study on its proprietary Amanita Muscaria Extract (AME-1).
“As pioneers bringing Amanita-derived products to market, Psyched Wellness is committed to ensuring that our proprietary extract, AME-1, is the safest extract available to consumers,” said Jeff Stevens, CEO of Psyched. “Our team prides itself on completing the necessary scientific studies to safely bring dietary supplements to market.”
The Company is also pleased to announce the successful completion of a production run for AME-1 and Calm. This production run is expected to provide Psyched with the necessary inventory to fulfill its online and retail orders for Calm and support sufficient supply of extract for the new dietary supplement being developed by Zerkalo LLC (“Zerkalo“), consultants to Psyched. Psyched continues to work towards securing a long-term manufacturing agreement to meet its growing needs and will provide further updates, as necessary, at the relevant time.
Zerkalo is making significant progress in developing new dietary supplement products using AME-1. The Company looks forward to sharing updates on the products and branding at the appropriate time.
Upcoming Annual General and Special Meeting (AGSM)
The Company has scheduled its next AGSM for May 15, 2025. The meeting materials including notice of meeting and record date, management information circular, form of proxy and voting instruction form (the “Materials“) shall be available on the Company’s profile on SEDAR+ at www.sedarplus.ca.
Psyched Wellness will be growing their route-to-market partnerships, throughout the nation. If you are interested in distributing/listing Calm, please reach out to sales@psyched-wellness.com.
For further information, please contact:
Jeffrey Stevens
Chief Executive Officer
Psyched Wellness Ltd.
Tel: 647-400-8494
Email: jstevens@psyched-wellness.com
Neither the Canadian Securities Exchange nor its Regulation Services Provider have reviewed or accept responsibility for the adequacy or accuracy of this release.
About Psyched Wellness Ltd.:
Psyched Wellness Ltd. is a Canadian-based health supplements company dedicated to researching and producing consumer packaged goods products derived from our proprietary extract of the Amanita Muscaria mushroom, AME-1.